埃索美拉唑联合生长抑素治疗重症胰腺炎的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Esomeprazole combined with Somatostatin(SS)in the treatment of severe acute pancreatitis (SAP)and its effect on intestinal mucosal barrier function and inflammatory transmitter levels.Methods A total of 84 cases of patients with SAP treated in our hospital from October 2015 to October 2017 were selected as objects and randomly divided into the control group and the observation group,with 42 cases in each group.The control group was given conventional symptomatic support,and the observation group was given Esomeprazole combined with SS on the basis of the control group.The symptom indicators,overall treatment effects,intestinal mucosal barrier function and inflammatory transmitter levels were compared between the two groups after treatment.Results After treatment,the relief time of abdominal pain and abdominal distension,the exhaust recovery time and the serum amylase recovery time in the observation group were significantly shorter than those in the control group,and the differences were statistically significant(P＜0.05).The rate of total clinical effective in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P＜0.05).The levels of D-lactic acid,DAO,endotoxin and L/M in the two groups after treatment were lower than those before treatment,and the differences were statistically significant(P＜0.05).The levels of D-lactic acid,DAO,endotoxin and L/M in the observation group after treatment were lower than those in the control group,and the differences were statistically significant(P＜0.05).The levels of IL-6,IL-8,CRP,and TNF-α in the two groups after treatment were lower than those before treatment,and the differences were statistically significant(P＜0.05).The levels of IL-6,IL-8,CRP,and TNF-α in the observation group after treatment were lower than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion Esomeprazole combined with SS for SAP can improve the symptoms and the treatment effective rate,promote the recovery of intestinal mucosal barrier function and reduce the levels of inflammatory mediators,which is worthy of clinical application.

Key words： Esomeprazole Somatostatin Severe acute pancreatitis Intestinal mucosal barrier function Inflammatory transmitter

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Ting
	WU Jian-wei
	TANG Hong-ling
	CHENG Yan-lin

Cite this article:

YANG Ting,WU Jian-wei,TANG Hong-ling, et al. Effect of Esomeprazole combined with Somatostatin in the treatment of severe acute pancreatitis[J]. 中国当代医药, 2018, 25(23): 166-168.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I23/166

[1]	田飞龙，闫明先.重症急性胰腺炎与肠道屏障功能障碍[J].中华临床医师杂志（电子版），2015，9（6）：1007-1010.
[2]	王瑞，黄志寅，王默进，等.防治重症急性胰腺炎临床研究进展[J].中华内科杂志，2016，55（6）：490-493.
[3]	王春峰，张连峰，张宇恒.埃索美拉唑对重症急性胰腺炎患者血清因子的影响[J].中国现代医学杂志，2013，23（17）：44-47.
[4]	郭现芳，勇彤，张伟平.生长抑素治疗急性胰腺炎的研究进展[J].现代消化及介入诊疗，2015，20（4）：455-457.
[5]	中华医学会外科学分会胰腺外科学组.急性胰腺炎诊治指南（2014）[J].中华普通外科杂志，2015，30（1）：69-72.
[6]	田笑笑，杜浩，白艳丽，等.埃索美拉唑联合早期肠内营养治疗重症急性胰腺炎的临床研究[J].实用医学杂志，2015，31（10）：1695-1698.
[7]	李凤舞，苗彬，王红.急性胰腺炎伴肠道屏障功能障碍的机制及检测方法[J].临床和实验医学杂志，2014，13（20）：1741-1745.
[8]	余贤恩.急性胰腺炎流行病学及严重性预测评估研究进展[J].胃肠病学和肝病学杂志，2015，24（2）：234-237.
[9]	何文华，祝荫，刘丕，等.1992版和2012版亚特兰大分类标准对急性胰腺炎病情严重程度判定的差异[J].中华内科杂志，2016，55（1）：21-24.
[10]	林旭红，李永渝.急性胰腺炎发病机制及相关治疗的研究进展[J].中国病理生理杂志，2010，26（5）：1029-1032.
[11]	罗桂金，雷平光，余洁梅，等.生长抑素联合质子泵抑制剂治疗重症胰腺炎患者的临床效果及对二胺氧化酶、D-乳糖的影响[J].广西医科大学学报，2016，33（3）：433-436.
[12]	陈曦，孙霞，夏兴洲，等.埃索美拉唑联合生长抑素治疗重症胰腺炎的临床研究[J].中国临床药理学杂志，2016，32（14）：1279-1282.
[13]	袁景，崔平，王建强.生长抑素联合泮托拉唑治疗急性胰腺炎的疗效及对炎症递质的影响[J].现代中西医结合杂志，2015，24（4）：397-399.
[14]	张红英，张宁宁，牛丹，等.血必净联合埃索美拉唑治疗重症急性胰腺炎的疗效观察[J].现代中西医结合杂志，2018，27（4）：387-389.
[15]	李蕾蕾，李强，王宏，等.生长抑素联合埃索美拉唑治疗门静脉高压性上消化道出血[J].现代生物医学进展，2016，16（35）：6939-6941.